Skin & hair

Methotrexate, the Old Reliable for Psoriasis

Save

Methotrexate has been treating psoriasis since long before biologics existed, and it's still what many people start on once creams and light therapy aren't enough. It isn't glamorous — weekly pills or an injection, routine blood draws, a slow build to full effect — but it works for a large share of people and costs a fraction of what a biologic does. Here is what actually happens once it's prescribed.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

What is methotrexate, and why is it still used?

This article assumes psoriasis has already been diagnosed rather than walking through an inflammatory rash differential against eczema or a fungal cause — that's a separate question from what to expect once methotrexate is actually prescribed. Methotrexate is an immune-modulating medication that has been used to treat moderate-to-severe psoriasis for decades, well before biologic drugs existed. It works by interfering with folate metabolism in rapidly dividing cells, which dampens the overactive immune signaling and the excessive skin-cell turnover that drive psoriasis plaques. Unlike most topical treatments, it's taken systemically — by mouth or as a self-injection — on a weekly rather than daily schedule, a pattern that surprises people used to daily pills.

It has stayed in regular use for reasons that have nothing to do with novelty: it's inexpensive relative to biologics, decades of use have made its safety profile well understood, and it treats the joint pain and stiffness of psoriatic arthritis as well as skin plaques and nail psoriasis, which not every psoriasis treatment reaches equally. For many people, methotrexate remains an effective, well-studied option even in an era of newer, flashier drugs.

Where does it sit in the psoriasis treatment ladder?

Psoriasis treatment generally starts with the least invasive option likely to work and escalates from there. Mild, limited disease is usually managed with topical treatments — corticosteroids and steroid-sparing agents like vitamin D analogs applied directly to plaques 1. How is psoriasis severity measured guides the next step more than any fixed rule: clinicians weigh how much body surface area is involved and how disruptive the disease is. Methotrexate enters the picture once disease is more extensive, involves the joints, or hasn't responded adequately to topicals and phototherapy — a different situation from guttate psoriasis, a distinct subtype that can follow a strep infection and is often self-limited enough to manage with topicals or phototherapy alone.

The case for moving to a systemic treatment like methotrexate isn't only cosmetic. Psoriasis carries meaningful associated risk for psoriatic arthritis, metabolic syndrome, and mood conditions, which is why current guidelines call for screening for and addressing these alongside the skin itself 2. Psoriasis is also associated with a higher risk of cardiovascular disease that tracks with how severe and widespread the skin disease is, likely reflecting shared inflammatory pathways rather than coincidence 3. Because of this, clinicians increasingly treat moderate-to-severe psoriasis as a systemic condition rather than a purely visible one — part of the reasoning for reaching for methotrexate rather than stronger topicals alone.

What does starting methotrexate actually involve?

Before the first dose, clinicians order baseline bloodwork — liver function, kidney function, and a complete blood count — along with screening for hepatitis and, for anyone who could become pregnant, a pregnancy test, since methotrexate is not safe in pregnancy. Most people also start a folic acid supplement alongside methotrexate, which meaningfully reduces the nausea, mouth soreness, and fatigue that are among its most common side effects without blunting how well it treats psoriasis.

Methotrexate takes longer to show its full effect than many people expect — meaningful improvement in plaques often takes a couple of months to become clear, and the full benefit can take longer still, a different rhythm than the fast relief a topical steroid provides. Formulation is a genuine choice: an oral tablet is simpler, while a subcutaneous injection is absorbed more predictably and can cause less stomach upset for people who don't tolerate the oral form well — a conversation worth having with a prescriber rather than assuming one form is automatically better.

What side effects are common, and what gets monitored?

The most common side effects — nausea, fatigue, mild hair thinning, and mouth sores — tend to show up in the day or two after a dose and often ease over time, especially with folic acid on board. Less common but more closely watched are effects on the liver and bone marrow: methotrexate can raise liver enzymes or reduce blood cell counts, which is why regular bloodwork continues for as long as someone is taking it, not just at the start.

Alcohol adds to the strain methotrexate already puts on the liver, so limiting or avoiding it is a standard part of the conversation when starting treatment. A rare but serious effect is lung inflammation, which is why new shortness of breath or a persistent cough during treatment is something to flag promptly rather than waiting for a routine visit. None of these risks are a reason to avoid methotrexate on their own — they're the reason the bloodwork schedule exists, catching problems while they're still easily reversible.

Who shouldn't take methotrexate?

Pregnancy is the clearest line: methotrexate can cause miscarriage and serious birth defects, so it isn't used during pregnancy, and reliable contraception is part of the plan for anyone who could become pregnant while taking it. Significant liver disease, heavy or regular alcohol use, and significant kidney impairment are also reasons a clinician might steer toward a different treatment, since methotrexate is cleared by the kidneys and processed by the liver.

An active infection, a low blood count from another cause, or a history of certain blood or liver conditions are also weighed carefully before starting. None of this is a fixed list to self-screen against — it's the kind of history a prescriber reviews in detail before writing the first prescription, which is part of why the workup takes more than one visit.

When does methotrexate stop being enough?

Not everyone responds fully to methotrexate, and even for people who do, psoriasis can progress or the joints can become more involved over time. When skin disease doesn't respond adequately, or when psoriatic arthritis is active and more aggressive, a biologic medication — targeting a more specific part of the immune pathway than methotrexate's broader effect — is the next tier in the psoriasis treatment ladder 4. Reading psoriasis biologics compared side by side shows how differently they work, and choosing a psoriasis biologic from among them factors in disease pattern, other health conditions, and personal preference.

For active psoriatic arthritis specifically, current joint guidelines have shifted: rather than treating methotrexate as the automatic first step, they give a conditional recommendation favoring a TNF-inhibitor biologic over oral options like methotrexate as first-line therapy for active joint disease 5, reflecting how much more targeted, and for the joints how much more reliably effective, biologics have proven to be. That doesn't make methotrexate obsolete — many people still do well on it, especially for skin-predominant disease, and it's sometimes combined with a biologic rather than replaced by one.

What else is worth knowing about the alternatives?

Phototherapy — controlled exposure to ultraviolet light, delivered in a clinic or occasionally at home — is another option, sometimes used instead of methotrexate and sometimes alongside it, with its own indications, schedule, and side effects that a dermatologist weighs against methotrexate for a given person 6. Neither is inherently better; the right choice depends on how severe the disease is, what else is going on health-wise, and what fits a person's schedule and preferences.

Most people on methotrexate for psoriasis do reasonably well, with side effects that are manageable and caught early through routine bloodwork rather than experienced as a surprise. The medication's long track record is, in a real sense, its main selling point: decades of use across a huge number of people means its risks and benefits are about as well understood as any drug in dermatology.

Common questions

Most people notice initial improvement within a few weeks, but the fuller effect typically takes a couple of months to become clear, and it can continue improving somewhat beyond that. It's a slower medication than a topical steroid, which is worth expecting going in rather than judging it as ineffective too early.

Yes, methotrexate is used for both the skin and joint sides of psoriatic disease, which is one reason it's often chosen when both are present. That said, current joint-specific guidelines increasingly favor a biologic as first-line for active psoriatic arthritis, so the choice depends on how active the joint disease is.

Because it can affect the liver and blood cell counts in a small number of people, and those changes usually show up in bloodwork before they cause symptoms. Regular monitoring is how those changes get caught early, while they're still reversible, rather than after they've become a bigger problem.

Alcohol adds to the strain methotrexate already places on the liver, so limiting or avoiding it is a standard part of treatment, and it's worth discussing specifics — including how much, if any, is considered acceptable — directly with the prescribing clinician rather than guessing.

Folic acid replaces some of the folate that methotrexate depletes, and it meaningfully reduces common side effects like nausea, mouth soreness, and fatigue without reducing how well methotrexate controls psoriasis. It's typically taken on a separate schedule from the methotrexate itself, as directed by the prescriber.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When to contact a clinician while on methotrexate

  • —New or worsening shortness of breath, or a persistent cough, during treatment
  • —Yellowing of the skin or eyes, dark urine, or unusual bruising or bleeding
  • —Fever, mouth ulcers, or signs of infection while on treatment
  • —A missed period or possible pregnancy while taking methotrexate

This article is general health information, not a treatment plan. Methotrexate requires an individualized workup, dosing decision, and monitoring schedule set by a prescriber — this article does not state a dose or a monitoring interval, both of which vary by person.

References

  1. 1.American Academy of Dermatology; National Psoriasis Foundation (2021). Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. Journal of the American Academy of Dermatology. PMID 32738429 ✓That topical corticosteroids and steroid-sparing agents such as vitamin D analogs are the first-line treatment for mild, limited psoriasis before systemic treatment is considered.
  2. 2.American Academy of Dermatology; National Psoriasis Foundation (2019). Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. Journal of the American Academy of Dermatology. PMID 30772097 ✓That current guidelines call for screening psoriasis patients for psoriatic arthritis, cardiovascular disease, metabolic syndrome, and psychiatric comorbidity alongside treating the skin.
  3. 3.Garshick MS, Ward NL, Krueger JG, Berger JS (2021). Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week. Journal of the American College of Cardiology. doi:10.1016/j.jacc.2021.02.009That psoriasis is associated with increased cardiovascular disease risk driven by systemic inflammation, with higher risk in more severe disease.
  4. 4.American Academy of Dermatology; National Psoriasis Foundation (2019). Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal of the American Academy of Dermatology. PMID 30772098 ✓That biologic agents targeting specific immune pathways form the next tier of the psoriasis treatment ladder for disease that doesn't respond adequately to conventional systemic therapy.
  5. 5.Singh JA, Guyatt G, Ogdie A, et al. (2019). 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Care & Research / Arthritis & Rheumatology. PMID 30499246 ✓That current ACR/NPF guidance gives a conditional recommendation to use a TNF-inhibitor biologic over oral small-molecule drugs, including methotrexate, as first-line therapy for active psoriatic arthritis.
  6. 6.American Academy of Dermatology; National Psoriasis Foundation (2019). Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with phototherapy. Journal of the American Academy of Dermatology. PMID 31351884 ✓That phototherapy (narrowband/broadband UVB, PUVA, excimer laser) is an alternative or adjunct systemic-adjacent treatment for psoriasis, with its own indications, dosing, and adverse effects.

6 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — citations link their sources. Editorial policy

← Back to the health library